Esperion Therapeutics Inc. (NASDAQ:ESPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The firm currently has a $16.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research’s price objective points to a potential upside of 18.26% from the company’s current price.

According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “

A number of other analysts have also recently commented on ESPR. WallachBeth Capital cut Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price target on the stock. in a research report on Tuesday, July 5th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price target (down from $77.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. JPMorgan Chase & Co. set a $15.00 price target on Esperion Therapeutics and gave the stock a “hold” rating in a research report on Friday, August 5th. Barclays PLC set a $13.00 price target on Esperion Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 31st. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $64.00 price target on shares of Esperion Therapeutics in a research report on Thursday, September 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.54.

Esperion Therapeutics (NASDAQ:ESPR) opened at 13.53 on Wednesday. The company’s market capitalization is $305.10 million. Esperion Therapeutics has a one year low of $9.58 and a one year high of $30.41. The firm’s 50-day moving average price is $12.01 and its 200 day moving average price is $14.07.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same period in the prior year, the firm earned ($0.55) EPS. On average, equities research analysts expect that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of Esperion Therapeutics by 42.4% in the second quarter. JPMorgan Chase & Co. now owns 142,161 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 42,361 shares in the last quarter. Swiss National Bank raised its stake in Esperion Therapeutics by 7.2% in the second quarter. Swiss National Bank now owns 22,200 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 1,500 shares during the period. Quantitative Investment Management LLC bought a new stake in Esperion Therapeutics during the second quarter valued at approximately $111,000. California State Teachers Retirement System raised its stake in Esperion Therapeutics by 8.1% in the second quarter. California State Teachers Retirement System now owns 30,016 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 2,251 shares during the period. Finally, FNY Managed Accounts LLC bought a new stake in Esperion Therapeutics during the second quarter valued at approximately $1,976,000. Institutional investors and hedge funds own 65.22% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.